Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen

David R. Gandara, Howard Wold, Edith A. Perez, Albert B. Deisseroth, J. Doroshow, F. Meyers, K. Mcwhirter, J. Hannigan, Michael W. De Gregorio

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Between October 1985 and March 1987, 92 patients were registered on a phase II study of the Northern California Oncology Group investigating the importance of dose intensity in the treatment of advanced non-small cell lung cancer (NSCLC). Treatment consisted of high-dose cisplatin in hyper-tonic saline (200 mg/m2 on a 28-day cycle) given in a divided day 1 and day 8 schedule. The response rate among 76 assessable patients was 36% (27/76), with complete response (CR) in 8% (6/76) and partial response (PR) in 28% (21/76). If all patients receiving any drug therapy were considered, the overall response rate was 31% (27/87), with CR in 7% (6/87) and PR in 24% (21/87). Median survival times for all assessable patients and all patients receiving any therapy were 37 and 35 weeks, respectively. With the use of a protocol design specifying dose delays rather than dose reduction for toxicity, the mean dose intensity delivered was 47.2 mg/m2 per week, or 94% of projected. Compared with other dose-intensive regimens of cisplatin, this day 1 and day 8 schedule was relatively well tolerated, with peripheral neuropathy as the dose-limiting toxicity. The data on response and median survival times among paptients receiving this singleagent therapy are encouraging. They support the potential importantce of cisplatin dose intensity in the treatment of NSCLC. Whether these results represent a positive dose-response effect in NSCLC will be tested in a randomized comparative trial of high-dose versus standard-dose cisplatiin therpaty.

Original languageEnglish (US)
Pages (from-to)790-794
Number of pages5
JournalJournal of the National Cancer Institute
Volume81
Issue number10
DOIs
StatePublished - May 22 1989
Externally publishedYes

Fingerprint

Cisplatin
Lung Cancer
Non-Small Cell Lung Carcinoma
Toxicity
Dose
Cells
Drug therapy
Oncology
Cell
Appointments and Schedules
Therapy
Therapeutics
Survival
Survival Time
Peripheral Nervous System Diseases
Schedule
Lung cancer
Partial
Drug Therapy
Dose-response

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Cancer Research

Cite this

Gandara, D. R., Wold, H., Perez, E. A., Deisseroth, A. B., Doroshow, J., Meyers, F., ... De Gregorio, M. W. (1989). Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen. Journal of the National Cancer Institute, 81(10), 790-794. https://doi.org/10.1093/jnci/81.10.790

Cisplatin dose intensity in non-small cell lung cancer : Phase II results of a day 1 and day 8 high-dose regimen. / Gandara, David R.; Wold, Howard; Perez, Edith A.; Deisseroth, Albert B.; Doroshow, J.; Meyers, F.; Mcwhirter, K.; Hannigan, J.; De Gregorio, Michael W.

In: Journal of the National Cancer Institute, Vol. 81, No. 10, 22.05.1989, p. 790-794.

Research output: Contribution to journalArticle

Gandara, DR, Wold, H, Perez, EA, Deisseroth, AB, Doroshow, J, Meyers, F, Mcwhirter, K, Hannigan, J & De Gregorio, MW 1989, 'Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen', Journal of the National Cancer Institute, vol. 81, no. 10, pp. 790-794. https://doi.org/10.1093/jnci/81.10.790
Gandara, David R. ; Wold, Howard ; Perez, Edith A. ; Deisseroth, Albert B. ; Doroshow, J. ; Meyers, F. ; Mcwhirter, K. ; Hannigan, J. ; De Gregorio, Michael W. / Cisplatin dose intensity in non-small cell lung cancer : Phase II results of a day 1 and day 8 high-dose regimen. In: Journal of the National Cancer Institute. 1989 ; Vol. 81, No. 10. pp. 790-794.
@article{72c824a1e557429eb71888d74d8d6c9b,
title = "Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen",
abstract = "Between October 1985 and March 1987, 92 patients were registered on a phase II study of the Northern California Oncology Group investigating the importance of dose intensity in the treatment of advanced non-small cell lung cancer (NSCLC). Treatment consisted of high-dose cisplatin in hyper-tonic saline (200 mg/m2 on a 28-day cycle) given in a divided day 1 and day 8 schedule. The response rate among 76 assessable patients was 36{\%} (27/76), with complete response (CR) in 8{\%} (6/76) and partial response (PR) in 28{\%} (21/76). If all patients receiving any drug therapy were considered, the overall response rate was 31{\%} (27/87), with CR in 7{\%} (6/87) and PR in 24{\%} (21/87). Median survival times for all assessable patients and all patients receiving any therapy were 37 and 35 weeks, respectively. With the use of a protocol design specifying dose delays rather than dose reduction for toxicity, the mean dose intensity delivered was 47.2 mg/m2 per week, or 94{\%} of projected. Compared with other dose-intensive regimens of cisplatin, this day 1 and day 8 schedule was relatively well tolerated, with peripheral neuropathy as the dose-limiting toxicity. The data on response and median survival times among paptients receiving this singleagent therapy are encouraging. They support the potential importantce of cisplatin dose intensity in the treatment of NSCLC. Whether these results represent a positive dose-response effect in NSCLC will be tested in a randomized comparative trial of high-dose versus standard-dose cisplatiin therpaty.",
author = "Gandara, {David R.} and Howard Wold and Perez, {Edith A.} and Deisseroth, {Albert B.} and J. Doroshow and F. Meyers and K. Mcwhirter and J. Hannigan and {De Gregorio}, {Michael W.}",
year = "1989",
month = "5",
day = "22",
doi = "10.1093/jnci/81.10.790",
language = "English (US)",
volume = "81",
pages = "790--794",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Cisplatin dose intensity in non-small cell lung cancer

T2 - Phase II results of a day 1 and day 8 high-dose regimen

AU - Gandara, David R.

AU - Wold, Howard

AU - Perez, Edith A.

AU - Deisseroth, Albert B.

AU - Doroshow, J.

AU - Meyers, F.

AU - Mcwhirter, K.

AU - Hannigan, J.

AU - De Gregorio, Michael W.

PY - 1989/5/22

Y1 - 1989/5/22

N2 - Between October 1985 and March 1987, 92 patients were registered on a phase II study of the Northern California Oncology Group investigating the importance of dose intensity in the treatment of advanced non-small cell lung cancer (NSCLC). Treatment consisted of high-dose cisplatin in hyper-tonic saline (200 mg/m2 on a 28-day cycle) given in a divided day 1 and day 8 schedule. The response rate among 76 assessable patients was 36% (27/76), with complete response (CR) in 8% (6/76) and partial response (PR) in 28% (21/76). If all patients receiving any drug therapy were considered, the overall response rate was 31% (27/87), with CR in 7% (6/87) and PR in 24% (21/87). Median survival times for all assessable patients and all patients receiving any therapy were 37 and 35 weeks, respectively. With the use of a protocol design specifying dose delays rather than dose reduction for toxicity, the mean dose intensity delivered was 47.2 mg/m2 per week, or 94% of projected. Compared with other dose-intensive regimens of cisplatin, this day 1 and day 8 schedule was relatively well tolerated, with peripheral neuropathy as the dose-limiting toxicity. The data on response and median survival times among paptients receiving this singleagent therapy are encouraging. They support the potential importantce of cisplatin dose intensity in the treatment of NSCLC. Whether these results represent a positive dose-response effect in NSCLC will be tested in a randomized comparative trial of high-dose versus standard-dose cisplatiin therpaty.

AB - Between October 1985 and March 1987, 92 patients were registered on a phase II study of the Northern California Oncology Group investigating the importance of dose intensity in the treatment of advanced non-small cell lung cancer (NSCLC). Treatment consisted of high-dose cisplatin in hyper-tonic saline (200 mg/m2 on a 28-day cycle) given in a divided day 1 and day 8 schedule. The response rate among 76 assessable patients was 36% (27/76), with complete response (CR) in 8% (6/76) and partial response (PR) in 28% (21/76). If all patients receiving any drug therapy were considered, the overall response rate was 31% (27/87), with CR in 7% (6/87) and PR in 24% (21/87). Median survival times for all assessable patients and all patients receiving any therapy were 37 and 35 weeks, respectively. With the use of a protocol design specifying dose delays rather than dose reduction for toxicity, the mean dose intensity delivered was 47.2 mg/m2 per week, or 94% of projected. Compared with other dose-intensive regimens of cisplatin, this day 1 and day 8 schedule was relatively well tolerated, with peripheral neuropathy as the dose-limiting toxicity. The data on response and median survival times among paptients receiving this singleagent therapy are encouraging. They support the potential importantce of cisplatin dose intensity in the treatment of NSCLC. Whether these results represent a positive dose-response effect in NSCLC will be tested in a randomized comparative trial of high-dose versus standard-dose cisplatiin therpaty.

UR - http://www.scopus.com/inward/record.url?scp=0024402301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024402301&partnerID=8YFLogxK

U2 - 10.1093/jnci/81.10.790

DO - 10.1093/jnci/81.10.790

M3 - Article

C2 - 2541260

AN - SCOPUS:0024402301

VL - 81

SP - 790

EP - 794

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -